Drug Profile
Research programme: hepatitis B therapeutics - Janssen Sciences Ireland/University of the Witwatersrand
Alternative Names: Anti-HBV TALENs - Janssen Sciences Ireland/University of the Witwatersrand; Anti-HBV therapy - Janssen Sciences Ireland/University of the WitwatersrandLatest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Janssen Sciences Ireland UC; University of the Witwatersrand
- Class Antivirals
- Mechanism of Action DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Hepatitis-B in South Africa
- 11 Jun 2015 The University of the Witwatersrand and Janssen Sciences Ireland UC agree to co-develop gene therapy in South Africa for Hepatitis B treatment
- 11 Jun 2015 Early research in Hepatitis B treatment in South Africa (unspecified route)